title: Edaravone ameliorates oxidative damage associated with Aβ25-35 treatment in PC12 cells.
abstract: Oxidative damage is an important mediator of Alzheimer's disease (AD); hence, antioxidant therapy is a potential treatment for AD. Edaravone, a free radical scavenger, has been shown to have neuroprotective properties. The study aimed to examine the effects of edaravone on indicators of Aβ25-35-induced oxidative damage in PC12 cells. PC12 cells were treated with 20, 40, or 80 μM edaravone before treatment with 30 μM Aβ25-35. After treatment, the following assessments were performed: cell viability and aggregation, oxidative stress, mitochondrial peroxidation, generation of reactive oxygen species (ROS), and apoptosis. Aggregation, lactate dehydrogenase activity, malondialdehyde concentrations, mitochondrial peroxidation, ROS levels, and apoptosis were significantly increased in Aβ25-35-treated cells but decreased in the treatment with edaravone 40 and 80 μM. In contrast, intracellular glutathione and superoxide dismutase concentrations were significantly decreased in Aβ25-35-treated cells but increased in the treatment with edaravone 40 and 80 μM. Edaravone ameliorates oxidative damage associated with Aβ25-35 treatment in PC12 cells. Our findings support the continued investigation of edaravone as a potential treatment for AD.
authors: Department of Neurology, the Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, No. 157 West 5 Road, Xi'an, 710004, Shaanxi Province, China. guilian_zhang@126.com
authors: Gui-lian
authors: GL
authors: Zhang
authors: Wang-gang
authors: WG
authors: Zhang
authors: Yun
authors: Y
authors: Du
authors: Li
authors: L
authors: Yao
authors: Hong
authors: H
authors: Sun
authors: Ru
authors: R
authors: Zhang
authors: Enqi
authors: E
authors: Liu
authors: Ning
authors: N
authors: Bu
authors: Hai-qin
authors: HQ
authors: Wu
authors: Lei
authors: L
authors: Zhang
authors: Ting-ting
authors: TT
authors: Li
authors: Ying-ying
authors: YY
authors: Guo
mesh_terms: D016229:Amyloid beta-Peptides / Q000633:toxicity*; D000818:Animals; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D000077553:Edaravone; D016166:Free Radical Scavengers / Q000494:pharmacology*; D005978:Glutathione / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008315:Malondialdehyde / Q000378:metabolism; D008928:Mitochondria / Q000378:metabolism; D018384:Oxidative Stress; D016716:PC12 Cells; D010446:Peptide Fragments / Q000633:toxicity*; D051381:Rats; D017382:Reactive Oxygen Species / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism
chemical_list: D016229:Amyloid beta-Peptides; D016166:Free Radical Scavengers; D010446:Peptide Fragments; D017382:Reactive Oxygen Species; C074636:amyloid beta-protein (25-35); D008315:Malondialdehyde; D013482:Superoxide Dismutase; D005978:Glutathione; D000077553:Edaravone; D000983:Antipyrine
references: Coll Antropol. 2011 Dec;35(4):1333-7
references: 22397284
references: Environ Toxicol Pharmacol. 2011 May;31(3):443-52
references: 21787715
references: Expert Rev Neurother. 2010 Jul;10(7):1201-8
references: 20586698
references: Antioxid Redox Signal. 2007 Oct;9(10):1647-58
references: 17696767
references: Curr Protein Pept Sci. 2010 Feb;11(1):54-67
references: 20201807
references: Alzheimers Dement. 2007 Jul;3(3):186-91
references: 19595937
references: Ann Pharmacother. 2005 Dec;39(12):2073-80
references: 16227450
references: Int J Angiol. 2010 Winter;19(4):e129-31
references: 22479143
references: J Alzheimers Dis. 2012;30(2):233-44
references: 22398376
references: Ageing Res Rev. 2009 Oct;8(4):285-305
references: 19376275
references: Cell. 2012 Mar 16;148(6):1204-22
references: 22424230
references: Brain Res Brain Res Rev. 1997 Dec;25(3):335-58
references: 9495562
references: Mol Biol Rep. 2012 Jun;39(6):6495-503
references: 22314911
references: J Neurochem. 2008 Sep;106(6):2345-52
references: 18643790
references: Nat Med. 2004 Jul;10 Suppl:S10-7
references: 15272267
references: Neuroscientist. 2002 Aug;8(4):323-34
references: 12194501
references: Annu Rev Pharmacol Toxicol. 2007;47:629-56
references: 17014364
references: Exp Neurol. 2010 Jan;221(1):26-37
references: 19751725
references: Int J Neurosci. 2012 Nov;122(11):665-74
references: 22757651
references: Naunyn Schmiedebergs Arch Pharmacol. 2011 Jul;384(1):103-8
references: 21533990
references: J Neurochem. 2006 Jan;96(1):1-13
references: 16305625
references: J Phys Chem B. 2011 Feb 10;115(5):1165-74
references: 21192698
references: J Biol Chem. 1995 Oct 13;270(41):23895-8
references: 7592576
references: PLoS One. 2011;6(6):e20677
references: 21677777
references: J Zhejiang Univ Sci B. 2006 Sep;7(9):749-56
references: 16909478
references: CNS Drug Rev. 2006 Spring;12(1):9-20
references: 16834755
references: Int J Biochem Cell Biol. 2012 Nov;44(11):2085-93
references: 22903022
references: Antioxid Redox Signal. 2006 Nov-Dec;8(11-12):1997-2006
references: 17034345
references: J Neurotrauma. 2011 Oct;28(10):2123-34
references: 21732763